Kalaris Therapeutics (KLRS) Stock Price, News & Analysis

Company Overview

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases, a group of eye conditions that can lead to vision loss. The company’s research is aimed at addressing diseases in which abnormal blood-vessel growth or leakage damages the retina.

Kalaris Therapeutics’ lead investigational product candidate is KAL-101, an experimental therapy being developed for retinal diseases. The company is advancing KAL-101 through clinical development and evaluating its potential to provide a treatment option for patients with conditions requiring ongoing management of retinal vascular abnormalities.

The company’s activities primarily center on research, clinical development, and the potential commercialization of ophthalmic medicines. Publicly available information about Kalaris Therapeutics’ operating history, geographic commercial presence, and leadership is limited.

Key Stats

• Today's Range: $1.78 to $1.88
• 50-Day Range: $1.80 to $4.20
• 52-Week Range: $1.78 to $11.88
• Volume: 50,127 shs
• Average Volume: N/A
• Market Capitalization: $44.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.75
• Consensus Rating: Moderate Buy

Kalaris Therapeutics Stock Analysis - MarketRank™

Kalaris Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 237th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kalaris Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Kalaris Therapeutics has a consensus price target of $18.75, representing about 908.1% upside from its current price of $1.86.

Amount of Analyst Coverage

Kalaris Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Kalaris Therapeutics are expected to remain at ($1.99) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kalaris Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kalaris Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.03% of the float of Kalaris Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kalaris Therapeutics has a short interest ratio ("days to cover") of 3.46, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kalaris Therapeutics has recently decreased by 7.68%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kalaris Therapeutics does not currently pay a dividend.

Dividend Growth

Kalaris Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

Kalaris Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Kalaris Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kalaris Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

68.10% of the stock of Kalaris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.05% of the stock of Kalaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KLRS
• CIK: 1754068
• Web: www.kalaristx.com
• Phone: (650) 249-2727
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kalaris Therapeutics: $18.75
• High Price Target: $25.00
• Low Price Target: $14.00
• Potential Upside/Downside: +908.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 23,805,000
• Free Float: 7,594,000
• Market Cap: $44.28 million
• Optionable: N/A
• Beta: 0.42